Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$88.85 USD

88.85
1,700,699

-0.15 (-0.17%)

Updated Oct 28, 2024 01:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Editas (EDIT) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.

The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Visa, Exxon Mobil, SAP, Union Pacific and Gilead Sciences

Sheraz Mian headshot

Top Research Reports for Tesla, Visa & Exxon Mobil

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Tesla (TSLA), Visa (V), and Exxon Mobil (XOM).

Will Jakafi's Performance Fuel Incyte's (INCY) Q1 Earnings?

by Zacks Equity Research

Investors are likely to focus on pipeline updates besides top and bottom-line numbers when Incyte (INCY) reports first-quarter 2021 results.

What's in Store for Vertex (VRTX) This Earnings Season?

by Zacks Equity Research

On Vertex's (VRTX) first-quarter earnings call, investor focus is likely to be on the sales performance of its triple combo CF drug Trikafta and the company's pipeline progress.

What's in Store for Emergent (EBS) This Earnings Season?

by Zacks Equity Research

On Emergent's (EBS) upcoming first-quarter earnings call, investors are likely to focus on the company's update related to re-start of production at its Bayview facility.

Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.

Will Strong Veklury and HIV Sales Aid Gilead's (GILD) Q1 Earnings?

by Zacks Equity Research

Investors will focus on the HIV franchise's performance and Veklury sales when Gilead (GILD) reports first-quarter 2021 results.

Is a Beat in Store for CRISPR (CRSP) This Earnings Season?

by Zacks Equity Research

On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.

Amgen (AMGN) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Whether Amgen's (AMGN) sales recovery from the COVID-19 effect continued in the first quarter is what remains to be seen when the company reports.

Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research

Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Roche (RHHBY) Q1 Sales Affected by Biosimilars & COVID-19

by Zacks Equity Research

Roche's (RHHBY) performance in the first quarter of 2021 gets negatively impacted by biosimilar competition and coronavirus-related disruptions. Nevertheless, the diagnostics division maintains momentum.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed at $66.38 in the latest trading session, marking a +0.65% move from the prior day.

Why Gilead (GILD) Could Beat Earnings Estimates Again

by Zacks Equity Research

Gilead (GILD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Lilly (LLY) to End Solo Bamlanivimab Use, Back COVID-19 Combo

by Zacks Equity Research

Lilly (LLY) plans to stop COVID-19 treatment with bamlanivimab alone in the United States. Instead, a combination of bamlanivimab and etesevimab will be available for the same, a better therapy for variants.

Biogen (BIIB) to Report Q1 Earnings: Will It Beat Estimates?

by Zacks Equity Research

Investor focus is likely to be on sales numbers of Tecfidera and Spinraza when Biogen (BIIB) reports first-quarter earnings.

Merck (MRK) Stops MK-7110 Development, Focuses on Molnupiravir

by Zacks Equity Research

Merck (MRK) will start evaluating oral molnupiravir in non-hospitalized COVID-19 patients in a late-stage study. It stops MK-7110 development due to requirement of additional studies.

Biotech Stock Roundup: GILD's UC Drug Approval, REGN's COVID-19 Antibody Data & More

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Gilead (GILD) and COVID-19 study updates from Regeneron (REGN), among others.

Gilead Sciences (GILD) Gains As Market Dips: What You Should Know

by Zacks Equity Research

Gilead Sciences (GILD) closed the most recent trading day at $65.30, moving +0.63% from the previous trading session.

Gilead (GILD) Gets FDA Nod for Trodelvy in Urothelial Cancer

by Zacks Equity Research

The FDA grants accelerated approval to Gilead's (GILD) Trodelvy for treating adult patients with locally-advanced or metastatic urothelial cancer.

Lilly's (LLY) JAK Inhibitor Olumiant Fails COVID-19 Study

by Zacks Equity Research

Lilly (LLY) and Incyte's Olumiant (baricitinib) in combination standard of care fails in a late-stage study evaluating it in hospitalized COVID-19 patients.

Gilead (GILD) Gets Full Approval for Breast Cancer Drug Trodelvy

by Zacks Equity Research

Gilead (GILD) obtains full approval for its breast cancer drug, Trodelvy, in the United States for metastatic triple-negative breast cancer.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Biotech Stock Roundup: ACAD Down on CRL, EBS Gets Additional Order & Other Updates

by Zacks Equity Research

The biotech sector was in focus last week with regulatory updates from Acadia (ACAD) and vaccine updates from quite a few companies like Emergent (EBS), among others.

Lilly's (LLY) Olumiant Dermatitis sNDA Review Gets Delayed

by Zacks Equity Research

The FDA extends the review period of Lilly (LLY)/Incyte's (INCY) label expansion application for Olumiant in atopic dermatitis by three months.